TY - JOUR
T1 - Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma
AU - Massari, Francesco
AU - Ciccarese, Chiara
AU - Porcaro, Antonio Bentito
AU - Ferrero, Stefano
AU - Gazzano, Giacomo
AU - Artibani, Walter
AU - Modena, Alessandra
AU - Bria, Emilio
AU - Sava, Teodoro
AU - Caliò, Anna
AU - Novara, Giacomo
AU - Ficarra, Vincenzo
AU - Chilosi, Marco
AU - Martignoni, Guido
AU - Bosari, Silvano
AU - Cheng, Liang
AU - Tortora, Giampaolo
AU - Brunelli, Matteo
PY - 2014
Y1 - 2014
N2 - We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.
AB - We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.
KW - Clear cell renal cell carcinoma
KW - Heat shock proteins
KW - HSP27
KW - HSP90
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84961290050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961290050&partnerID=8YFLogxK
U2 - 10.1097/PAT.0000000000000150
DO - 10.1097/PAT.0000000000000150
M3 - Article
AN - SCOPUS:84961290050
VL - 46
SP - 523
EP - 526
JO - Pathology
JF - Pathology
SN - 0031-3025
IS - 6
ER -